CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo.

Compared with the vehicle control, dinaciclib treatment was well tolerated and associated with a highly significant survival advantage of tumor-bearing mice, including those bearing a p53-null lymphoma and a lymphoma with a spontaneous p53 mutation encoding a dominant-negative p53 protein ( Figures 2a–c , Supplementary Figure S3 ).

also in 132,142 other papers